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Objectives
To investigate the patterns and frequency of multiple risk behaviours (alcohol, drugs, smoking,
higher risk sexual activity) among men who have sex with men (MSM) living with HIV.
Methods
Cross sectional study.
Results
819 HIV-positive MSM exhibited a high-risk phenotype (defined as >3 of smoking, excess alcohol,
sexually transmitted infection and recent recreational drug use). This phenotype was associated
with younger age, depressive symptoms and <90% adherence in multivariable logistic regression.
Conclusion
In a cohort of MSM, a small, but significant proportion exhibited multiple concurrent risk
behaviours.
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Introduction
As life expectancy has increased for people living with
HIV (PLHIV), the focus of HIV care has shifted towards
the prevention and treatment of noncommunicable dis-
eases (NCDs) [1]. Many NCDs are associated with factors
such as tobacco, alcohol and recreational drug use, which
are highly prevalent in PLHIV [2]. Although the health
effects of these behaviours are established, the pattern
and health impact of concurrent behaviours are not well
defined among PLHIV.
Syndemics theory highlights that behaviours do not
occur in a vacuum but can be intertwined and mutually
enhancing [3]. A strong association between use of alco-
hol/drugs and condomless sex was demonstrated in the
UK general population, and participants exhibiting these
behaviours were characterized as socio-economically
deprived and of white ethnicity [4]. An increased rate of
condomless sex with casual partners has been reported in
men who have sex with men (MSM) living with HIV, par-
ticularly in the context of chemsex [5,6]. Mental health
conditions, particularly anxiety and depression, are dis-
proportionately prevalent among PLHIV [7,8], and strong
associations have been reported between alcohol or drug
use and psychiatric conditions [9]. However, little is
known about the relationship between risk behaviours
and mental health conditions in older PLHIV.
In this study, we investigated the patterns and frequency
of multiple risk behaviours among MSM PLHIV
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participating in the Pharmacokinetic and Clinical Observa-
tions in People over Fifty (POPPY) study and investigated
whether the presence of multiple risk behaviours was asso-
ciated with markers of HIV disease or mental health prob-
lems.
Methods
POPPY is a prospective, cohort study conducted at seven
sites in the UK and Ireland that aims to investigate the
impact of HIV on comorbidities and pharmacotherapy
among PLHIV as they age [10]. The present analyses used
cross-sectional baseline data from HIV-positive POPPY
participants only collected at baseline POPPY visits
between April 2013 and February 2016.
Four key behaviours were considered: current smoking,
recreational drug use in the past 6 months, alcohol con-
sumption > 21 units/week and a diagnosed sexually
transmitted infection (STI) within the last 12 months. The
‘high-risk phenotype’ was defined as exhibiting three or
four of these behaviours. As almost all participants who
exhibited the high-risk phenotype were MSM (95%), the
analysis was restricted to this group.
Current depressive symptoms were measured via the
Patient Health Questionnaire (PHQ-9) and Center for Epi-
demiologic Studies Depression (CES-D) [11,12]. Adher-
ence to antiretroviral therapy (ART) was captured via a
self-completed questionnaire, and CD4 count and HIV
viral load were collected through linkage with national
cohorts [10].
Statistical analysis
We performed univariate analysis of associations with
the high-risk phenotype using Pearson’s v2 test for bin-
ary variables and logistic regression for categorical and
continuous variables. Logistic regression was also used
to investigate if the high-risk phenotype was associated
with an increased risk of mental health problems, poorer
ART adherence, detectable viral load and low CD4
count. Participants were classified as having a history of
mental health outcomes if they reported this in their
medical history, whereas a PHQ-9 score ≥ 5 and a CES-
D score ≥ 16 were considered as indicating current
depressive symptoms. Analyses of these outcomes were
adjusted for age, work status, whether the patient had
sufficient money, duration of HIV infection and number
of ART drugs to which the patient was exposed. ART
adherence was categorized as < 90%/≥ 90%, CD4 count
as < 350/> 350 cells/lL and viral load as < 50/
≥ 50 HIV-1 RNA copies/mL. Analyses of CD4 count and
viral load included adjustment for age, duration of HIV
infection and work status, whereas analyses of ART
adherence included adjustment for work status only
because of the low number of participants reporting
< 90% adherence. All analyses were conducted in STATA
(version 14, StataCorp LLC, College Station, Texas, USA).
Results
The median age of the 819 MSM was 52 (range 20–80)
years; 99.6% (816 of 819) were of white ethnicity. The
median time since HIV diagnosis was 14.5 (range 0–31)
years, 98.1% (803 of 819) were on ART, the median CD4
count was 630 (range 90–2513) cells/lL, and 90.8% (744
of 819) had a viral load < 50 copies/mL. Baseline charac-
teristics are reported elsewhere [10].
Over a quarter of participants (27.7%) were current
smokers, and 17.2% drank > 21 units of alcohol/week.
Around a third (34.2%) had used recreational drugs
within the past 6 months, most frequently cannabis, and
three-quarters (74.1%) reported an STI in the past
12 months, most frequently gonorrhoea and syphilis.
Only 103 participants (12.6%) reported no risk beha-
viours. Overall, 17.9% (147 of 819) participants reported
three or four of the behaviours and were defined as
exhibiting the high-risk phenotype. Within the high-risk
phenotype, the most frequently observed combination of
risk behaviours was smoking, drugs and STI, reported by
85 of 103 participants (57.8%). The combination of drugs,
alcohol and STI was reported by 29 (19.7%) participants
and that of smoking, alcohol and STI was reported by 14
(9.5%) participants. Eleven participants (7.5% within the
high-risk phenotype) reported all four risk behaviours.
The prevalence of the high-risk phenotype decreased
from 33.3% in those aged < 35 years to 9.1% in those
aged > 65 years. In univariate analyses, each 10-year
increment in age was associated with a reduction in the
odds of the high-risk phenotype of 29% (Table 1). No
other factor was independently associated with the high-
risk phenotype in adjusted analysis (Table 1).
In total, 320 participants (39.1%) reported a mental
health diagnosis, most commonly depression and anxiety;
64 of the 144 participants (44.4%) with the high-risk phe-
notype and 256 of the 675 participants (37.8%) without
it. There was no evidence of an association between the
high-risk phenotype and mental health diagnoses either
in unadjusted [odds ratio (OR) 1.31; 95% confidence
interval (CI) 0.91–1.88; P = 0.15] or adjusted (OR 1.29;
95% CI 0.86–1.92; P = 0.22) analyses. Of those with com-
plete data, 46.2% and 34.9% had scores consistent with
current depressive symptoms for PHQ-9 and CES-D
respectively. In contrast to the findings for mental health
diagnoses, there was strong evidence of an association
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between the high-risk phenotype and current depressive
symptoms, with 56.9 and 45.5% of those with the high-
risk phenotype reporting a PHQ-9 score > 5 and a CES-
D score > 16, respectively, compared with only 43.8 and
32.6% of those without the high-risk phenotype (PHQ-
9 > 5: aOR 1.82; 95% CI 1.12–2.75; P = 0.004; CES-
D > 16: aOR 1.83; 95% CI 1.20–2.79; P = 0.005).
Of participants on ART at baseline, only 33 (5%) reported
< 90% ART adherence in the past month (9.5% of those
with the high-risk phenotype and 3.0% of those without).
Participants exhibiting the high-risk phenotype were 3.32
times as likely to report < 90% adherence as those who did
not (aOR 3.32; 95% CI 1.61–6.87; P = 0.001). Fifty-nine
(7.3%) of those on ART at baseline had a detectable viral
load (11.1% of those with the high-risk phenotype and
8.3% of those without) and 71 (8.7%) had a CD4 count
< 350 cells/lL (6.3% of those with the high-risk phenotype
and 9.2% of those without). There was no evidence of an
association between the high-risk phenotype and either a
detectable viral load (aOR 1.13; 95% CI 0.61–2.07;
P = 0.70) or a low CD4 count (aOR 0.63; 95% CI 0.29–1.35;
P = 0.23) in adjusted analyses.
Table 1 Unadjusted and adjusted (for age) associations between participant characteristics and the high-risk phenotype
Characteristic Total
n (%) with
high-risk phenotype* Unadjusted OR (95% CI), P Adjusted OR (95% CI), P
Age (years)
Median (range) 51 (21, 81) 0.71 (0.59, 0.84), < 0.001 0.71 (0.59, 0.84) < 0.001
< 35 years 54 18 (33.3)
35–45 years 115 26 (22.6)
45–55 years 330 63 (19.1)
55–65 years 243 30 (12.3)
> 65 years 77 7 (9.1)
Country of birth
UK 595 100 (16.8) 1 1
Rest of the world 224 44 (19.6) 1.21 (0.82, 1.79), 0.34 1.05 (0.70, 1.57), 0.83
Work
Employed/full-time education 382 75 (19.6) 1 1
Unemployed 176 37 (21.0) 1.09 (0.70, 1.69), 0.70 1.25 (0.80, 1.97), 0.33
Retired 146 18 (12.3) 0.58 (0.33, 1.00), 0.05 0.99 (0.52, 1.88), 0.97
Unknown 115 14 (12.2) 0.57 (0.31, 1.05), 0.07 0.63 (0.34, 1.17), 0.14
Housing
Owned/rented 682 125 (18.3) 1 1
Insecurely housed 42 7 (16.7) 0.89(0.39, 2.05), 0.79 0.69 (0.29, 1.62), 0.40
Unknown 95 12 (12.6) 0.64 (0.34, 1.22), 0.18 0.59 (0.31, 1.11), 0.10
Enough money?
Yes, all the time 404 75 (18.6) 1 1
Yes, mostly 110 17 (15.5) 0.80 (0.45, 1.42), 0.45 0.71 (0.40, 1.28), 0.26
Yes, sometimes 46 13 (28.3) 1.73 (0.87, 3.44), 0.12 1.54 (0.76, 3.09), 0.23
No 10 0 (–) n/a n/a
Unknown 249 39 (15.7) 0.81 (0.53, 1.24), 0.34 0.78 (0.51, 1.20), 0.26
Education
≤ High school 183 31 (16.9) 1 1
A levels/college 198 37 (18.7) 1.13 (0.67, 1.91), 0.66 1.05 (0.62, 1.79), 0.86
≥ University degree 345 64 (18.6) 1.12 (0.70, 1.79), 0.65 1.00 (0.62, 1.62), 0.99
Unknown 93 12 (12.9) 0.73(0.35, 1.49), 0.38 0.63 (0.30, 1.30), 0.21
Time since HIV diagnosis
(years) [median (range)]
8 (0, 26) 0.99 (0.96, 1.01), 0.19 1.01 (0.98, 1.03), 0.69
On ART at baseline
Yes 803 137 (17.1) 1 1
No, ART na€ıve 6 3 (50.0) 4.86 (0.97, 24.34), 0.05 3.06 (0.60, 15.68), 0.179
No, previous use only 10 4 (40.0) 3.24 (0.90, 11.64), 0.07 2.47 (0.67, 9.08), 0.17
ART start date
≥ 2004 418 79 (18.9) 1 1
1996–2003 296 46 (15.5) 0.79 (0.53, 1.18), 0.25 1.04 (0.67, 1.60), 0.86
< 1996 95 15 (15.8) 0.80 (0.44, 1.47), 0.48 1.13 (0.60, 2.14), 0.71
Never been on ART 10 4 (40.0) 2.86 (0.79, 10.38), 0.11 2.44 (0.66, 9.06), 0.18
Number of unique ART drugs
[median (range)]
6 (0, 19) 0.97 (0.92, 1.03), 0.32 1.00 (0.95, 1.06), 0.98
ART, antiretroviral therapy; CI, confidence interval; OR, odds ratio.
*Unless otherwise stated.
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Discussion
In a cohort of HIV-positive MSM, we demonstrated the
presence of a ‘high-risk phenotype’ of multiple concur-
rent risk behaviours in a small but significant proportion
of participants. The likelihood of exhibiting this high-risk
phenotype decreased with increasing age, but was
demonstrable across all age groups. Such high-risk beha-
viours are commonly considered to be a phenomenon of
youth [4], but these data emphasize that drugs, alcohol,
smoking and STIs must be considered in all age groups
of HIV-positive MSM.
Mental health conditions and symptoms of depression
were common in this cohort; participants reporting the
high-risk phenotype had increased risks of all three mea-
sures of poor mental health status, consistent with the
findings from the general population [4]. Potential mech-
anisms for this relationship could include use of sub-
stances to cope with mental health symptoms, or risk of
mental health problems secondary to substance use [5].
In our analyses, participants who exhibited the high-
risk phenotype were three times more likely to report
< 90% ART adherence, consistent with data from the
USA, where alcohol consumption and drug use were asso-
ciated with poorer reported adherence among older PLHIV
[2]. The apparent inconsistency between our findings of
an association with 90% adherence but not with viral load
suppression may reflect the fact that modern ART regi-
mens do not require such high levels of adherence to
maintain viral suppression. Alternatively, our analyses
may be affected by responder bias (adherence was self-
reported) or by the fact that, while adherence was reported
for the month prior to interview, the viral load may have
been obtained up to 6 months prior to interview.
The strengths of our study include the large sample
size, standardized measurement of mental health condi-
tions, and linkage to national cohorts. While participants
were predominantly white cisgender MSM, limiting gen-
eralizability to other groups, the sample did broadly
reflect the demographics of MSM PLHIV in the UK [13].
We note that the small numbers of participants in some
subgroups may have resulted in lack of power, and
information on self-reported STIs and mental health
diagnoses may have been incomplete. Finally, the cross-
sectional nature of this study means that we were
unable to establish the direction of any relationships.
Our study provides new evidence of concurrent risk
behaviours in HIV-positive MSM. In addition to the iden-
tification of clustered high-risk behaviours in older age
groups, we have demonstrated associations between this
phenotype and current symptoms of depression and
poorer adherence, highlighting the clinical relevance of
this phenotype. Future research could investigate causal-
ity and the direction of the relationships observed
through use of longitudinal data.
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